[ANIK] Anika Therapeutics Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 49.53 Change: 0.9 (1.85%)
Ext. hours: Change: 0 (0%)

chart ANIK

Refresh chart

Strongest Trends Summary For ANIK

ANIK is in the long-term up 381% in 15 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Anika Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair in the United States, Europe, and internationally. The company?s products are based on hyaluronic acid (HA), a naturally occurring biocompatible polymer found in the body. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, and MONOVISC for the treatment of osteoarthritis of the knee and joints; Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells that is used in connection with soft tissue regeneration; Hyalonect, a woven gauze used as a graft wrap; Hyaloss used to mix blood/bone grafts to form a paste for bone regeneration; and Hyaloglide, an ACP gel used in tenolysis treatment. The company?s dermal products include wound care products that comprise Hyalomatrix and Hyalofill, for treatment of complex wounds, such as burns and ulcers; Hyalograft 3D and Laserskin scaffolds for use in connection with the regen

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS2.07 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -40.93% Sales Growth - Q/Q-33.26% P/E21.89
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA13.56% ROE14.74% ROI
Current Ratio23.7 Quick Ratio21.67 Long Term Debt/Equity Debt Ratio0.03
Gross Margin76.03% Operating Margin49.46% Net Profit Margin30.77% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.9 M Cash From Investing Activities-6.01 M Cash From Operating Activities3.98 M Gross Profit17.63 M
Net Profit7.82 M Operating Profit12.43 M Total Assets208.01 M Total Current Assets155.73 M
Total Current Liabilities7.96 M Total Debt Total Liabilities17.44 M Total Revenue22.9 M
Technical Data
High 52 week68.43 Low 52 week30.16 Last close33.37 Last change-1.68%
RSI28.12 Average true range1.5 Beta0.55 Volume53.19 K
Simple moving average 20 days-12.46% Simple moving average 50 days-5.2% Simple moving average 200 days-30.71%
Performance Data
Performance Week-15.56% Performance Month-8.45% Performance Quart-24.07% Performance Half-50.76%
Performance Year-35.45% Performance Year-to-date-0.71% Volatility daily3.96% Volatility weekly8.86%
Volatility monthly18.15% Volatility yearly62.89% Relative Volume229.99% Average Volume131.63 K
New High New Low

News

2019-09-04 16:05:00 | Anika Therapeutics to Host Analyst and Investor Day on September 18, 2019

2019-09-03 16:05:00 | Anika to Participate in the 2019 Morgan Stanley Global Healthcare Conference on September 10, 2019

2019-08-23 14:12:19 | Here's What Anika Therapeutics, Inc.'s NASDAQ:ANIK P/E Is Telling Us

2019-08-13 08:30:00 | Anika Announces Successful Completion of First Human Surgical Procedure with Injectable HA-Based Bone Repair Therapy

2019-07-29 09:55:00 | Anika Therapeutics Gets a Quant Upgrade to Buy, Adding to Its Technical Breakout

2019-07-26 11:17:00 | Harry Boxer’s four stock breakouts to watch

2019-07-26 11:06:34 | 4 Earnings Breakouts To Watch

2019-07-26 07:26:37 | The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint

2019-07-25 16:31:00 | Why Anika Therapeutics Stock Crushed It Today

2019-07-25 07:21:54 | The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug

2019-07-25 06:29:00 | Anika Therapeutics Blows Past Q2 Earnings Estimates

2019-07-25 00:24:14 | Anika Therapeutics Inc ANIK Q2 2019 Earnings Call Transcript

2019-07-24 18:35:10 | Anika Therapeutics ANIK Q2 Earnings and Revenues Surpass Estimates

2019-07-24 16:05:00 | Anika Reports Second Quarter 2019 Financial Results

2019-07-22 11:13:03 | What's in Store for Anika Therapeutics' ANIK Q2 Earnings?

2019-07-18 12:46:04 | Is Anika Therapeutics, Inc.'s NASDAQ:ANIK 11% ROE Worse Than Average?

2019-07-17 10:32:02 | Analysts Estimate Anika Therapeutics ANIK to Report a Decline in Earnings: What to Look Out for

2019-07-15 09:00:01 | Anika ANIK Moves to Buy: Rationale Behind the Upgrade

2019-07-11 08:00:00 | Anika to Exhibit its HA-Based Bone Repair Therapy at the 2019 American Orthopaedic Society for Sports Medicine Annual Meeting

2019-07-10 16:05:00 | Anika to Issue Second-Quarter 2019 Financial Results and Business Highlights on Wednesday, July 24

2019-07-08 08:00:00 | Anika Appoints James Loerop as Executive Vice President of Business Development and Strategic Planning

2019-06-28 10:10:02 | Novavax NVAX Seeks Accelerated Approval Pathway for NanoFlu

2019-06-25 08:00:12 | Alnylam Presents New Data for RNAi Therapeutic Onpattro

2019-06-24 17:53:09 | Epizyme Announces Positive Interim Data on Lead Candidate

2019-06-24 17:45:09 | AMAG's Vyleesi Gets FDA NOD for Women with Low Sexual Desire

2019-06-24 11:04:03 | BioMarin Gets $15M From Pfizer on Talzenna's European Nod

2019-06-24 10:05:02 | Vertex's VRTX Symdeko Gets FDA Nod for Use in Children

2019-06-24 08:40:12 | Moving Average Crossover Alert: Anika Therapeutics

2019-06-23 20:54:40 | Did Hedge Funds Drop The Ball On Is Anika Therapeutics, Inc. ANIK ?

2019-06-20 09:01:01 | Ultragenyx & Arcturus Therapeutics Expand Existing Agreement

2019-06-19 16:07:08 | Alexion's ALXN Ultomiris Gets Approval in Japan for PNH

2019-06-18 10:38:02 | Arena Initiates Dosing in Pivotal Colitis Study on Etrasimod

2019-06-18 09:58:01 | Alnylam Completes Enrollment in Phase III Study of Lumasiran

2019-06-17 18:17:10 | Alexion's ALXN PNH Drug Ultomiris Shows Long-Term Efficacy

2019-06-14 17:25:09 | Dr. Reddy's Inks Deal to Sell Neurology Branded Products

2019-06-13 17:46:09 | Catalyst Pharma Files Lawsuit Against FDA Approval of Ruzurgi

2019-06-13 10:26:02 | Alkermes Initiates Monothearpy Expansion Phase of ALKS 4230

2019-06-12 15:51:01 | Are Insiders Selling Anika Therapeutics, Inc. NASDAQ:ANIK Stock?

2019-06-12 09:39:01 | Zynerba Up on Second Patent for Cannabidiol Candidate in 2019

2019-06-11 18:18:10 | Novavax' Shares Drop as FDA Advises Another Study for Resvax

2019-06-10 17:30:09 | Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug

2019-06-06 15:26:07 | Incyte Begins Phase III Study for Treatment of Duct Cancer

2019-06-05 08:00:00 | Anika Announces Plans to Showcase HYALOFAST Hyaluronic Acid-Based Cartilage Repair Scaffold at the 2019 International Cartilage Regeneration and Joint Preservation Society ICRS Focus Meeting

2019-06-04 16:16:08 | bluebird's Zynteglo Gets EU Conditional Marketing Approval

2019-06-04 10:26:02 | Celldex Presents Data From CDX-3379 Study at ASCO, Stock Down

2019-06-04 09:01:01 | uniQure QURE Jumps: Stock Rises 8.9%

2019-06-03 16:48:08 | Alnylam Initiates Phase I Study on Hypertension Candidate

2019-05-30 08:44:12 | Fibrocell Up on FDA Designation for Gene Therapy Candidate

2019-05-30 08:28:12 | Amarin Rises on Priority Review for Vascepa Label Expansion

2019-05-29 10:40:02 | Mallinckrodt to Spin Off Specialty Generics Unit, Shares Down